STOCK TITAN

[144] Olema Pharmaceuticals, Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Cyrus L. Harmon has filed a notice of proposed sale of 10,000 shares of OLMA common stock under Rule 144. The shares are planned to be sold through Fidelity Brokerage Services LLC on or around 01/20/2026 on the NASDAQ, with an indicated aggregate market value of 268,762.74. The filing notes that 68,659,923 shares of OLMA common stock are outstanding.

The 10,000 shares were originally acquired on 03/20/2007 as founder shares, recorded as compensation. Over the prior three months, Harmon sold 2,881 OLMA common shares on 12/22/2025 for gross proceeds of 82,182.00 and 3,489 shares on 01/14/2026 for gross proceeds of 101,603.33. By signing the notice, the seller represents they are not aware of undisclosed material adverse information about the issuer.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Olema Pharmaceuticals, Inc.

NASDAQ:OLMA

OLMA Rankings

OLMA Latest News

OLMA Latest SEC Filings

OLMA Stock Data

2.18B
76.32M
3.31%
104.74%
12.26%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN FRANCISCO